G. Finlay

发表

Signaling Pathways in Melanogenesis

M. Askarian-Amiri, B. Baguley, Stacey D'Mello, 2016, International journal of molecular sciences.

Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs

B. Baguley, G. Finlay, 2000, Cancer Chemotherapy and Pharmacology.

Keeping abreast with long non-coding RNAs in mammary gland development and breast cancer

M. Askarian-Amiri, B. Baguley, G. Finlay, 2014, Front. Genet..

THE AMAZING PLACENTA: EVOLUTION AND LIFELINE TO HUMANNESS

G. Finlay, 2020, Zygon®.

Methods Used for Noncoding RNAs Analysis

M. Askarian-Amiri, D. Korbie, G. Finlay, 2016 .

Cytokinetic factors in drug resistance of Lewis lung carcinoma: comparison of cells freshly isolated from tumours with cells from exponential and plateau-phase cultures.

W. Wilson, B. Baguley, G. Finlay, 1987, British Journal of Cancer.

Centrosomal dysregulation in human metastatic melanoma cell lines.

A. Shelling, B. Baguley, G. Finlay, 2011, Cancer genetics.

Synthesis, antitumor activity, and DNA binding properties of a new derivative of amsacrine, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino) phenylamino]-4-acridinecarboxamide.

W. Denny, W. Wilson, G. Rewcastle, 1984, Cancer research.

Analysis of Melanoma Secretome for Factors That Directly Disrupt the Barrier Integrity of Brain Endothelial Cells

E. S. Graham, S. O'Carroll, G. Finlay, 2020, International journal of molecular sciences.

Endocrine Therapy of Estrogen Receptor-Positive Breast Cancer Cells: Early Differential Effects on Stem Cell Markers

M. Askarian-Amiri, B. Baguley, G. Finlay, 2017, Front. Oncol..

Unusual dynamics of killing of cultured lewis lung cells by the DNA-intercalating antitumour agentN-[2-(dimethylamino)ethyl]acridine-4-carboxamide

J. Gavin, B. Baguley, G. Finlay, 2004, Cancer Chemotherapy and Pharmacology.

A New Side of the Nicotinic Receptor

C. McArdle, D. Spandidos, F. Lee, 1998, Environmental Health Perspectives.

Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells

G. Rewcastle, J. Kim, B. Baguley, 2011, Cancer biology & therapy.

Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer.

P. V. van Zijl, B. Baguley, G. Finlay, 1995, European journal of cancer.

Subcellular distribution and photocytotoxicity of aluminium phthalocyanines and haematoporphyrin derivative in cultured human meningioma cells.

B. Baguley, G. Malham, G. Finlay, 1996, British journal of neurosurgery.

Insulin receptor regulation in cultured human tumor cells.

G. Finlay, K. Mountjoy, I. Holdaway, 1983, Cancer research.

Relationship of cell cycle parameters to in vitro and in vivo chemosensitivity for a series of Lewis lung carcinoma lines.

B. Baguley, G. Finlay, K. Holdaway, 1992, European journal of cancer.

The LAM cell: what is it, where does it come from, and why does it grow?

G. Finlay, G. Finlay, 2004, American journal of physiology. Lung cellular and molecular physiology.

Melanoma Mediated Disruption of Brain Endothelial Barrier Integrity Is Not Prevented by the Inhibition of Matrix Metalloproteinases and Proteases

G. Finlay, C. E. Angel, Scott E. Graham, 2022, Biosensors.

In vitro systems for anticancer drug testing

G. Finlay, 1992 .

Cytokinetic differences in the action ofN-[2-(dimethylamino)ethyl]acridine-4-carboxamide as compared with that of amsacrine and doxorubicin

B. Baguley, G. Finlay, A. Haldane, 2004, Cancer Chemotherapy and Pharmacology.

Ring-substituted 11-oxo-11H-indeno[1,2-b]quinoline-6-carboxamides with similar patterns of cytotoxicity to the dual topo I/II inhibitor DACA.

A. J. Kaye, W. Denny, M. Thompson, 1999, Bioorganic & medicinal chemistry.

Comparison of the cytotoxicity of amsacrine and its analogue CI-921 against cultured human and mouse bone marrow tumour cells.

B. Baguley, L. Ching, G. Finlay, 1990, European journal of cancer.

Effect of flavone acetic acid on Lewis lung carcinoma: evidence for an indirect effect.

G. P. Smith, B. Baguley, G. Finlay, 1988, Journal of the National Cancer Institute.

Anticancer drug sensitivity profiles of new and established melanoma cell lines.

B. Baguley, G. Finlay, E. Marshall, 1993, Oncology research.

Comparison of the effects of genistein and amsacrine on leukemia cell proliferation.

B. Baguley, G. Finlay, K. Holdaway, 1994, Oncology research.

In vitro methods for screening agents with an indirect mechanism of antitumour activity: xanthenone analogues of flavone acetic acid.

B. Baguley, L. Ching, G. Finlay, 1991, European journal of cancer.

Tumour tissue selectivity in the uptake and retention of SN 28049, a new topoisomerase II-directed anticancer agent

B. Baguley, G. Finlay, E. Richardson, 2013, Cancer Chemotherapy and Pharmacology.

Mechanism of cytotoxicity of N -[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II

B. Baguley, G. Finlay, D. J. Bridewell, 1999, Cancer Chemotherapy and Pharmacology.

Comprehensive Assessment of Secreted Immuno-Modulatory Cytokines by Serum-Differentiated and Stem-like Glioblastoma Cells Reveals Distinct Differences between Glioblastoma Phenotypes

E. S. Graham, G. Finlay, C. E. Angel, 2022, International journal of molecular sciences.

Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, 1994: PHARMACOKINETIC/CYTOKINETIC PRINCIPLES IN THE CHEMOTHERAPY OF SOLID TUMOURS

B. Baguley, G. Finlay, Bruce C. Baguley, 1995, Clinical and experimental pharmacology & physiology.

Diagnostic markers demonstrating successful culture of human meningioma cells

S. Edgar, B. Synek, G. Malham, 1995, Journal of Clinical Neuroscience.

Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide

B. Baguley, G. Finlay, E. Richardson, 2011, Investigational New Drugs.

Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.

J. A. Spicer, S. Gamage, W. Denny, 2001, Journal of medicinal chemistry.

Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIα and β

D. Sullivan, R. Lock, B. Baguley, 1999, Cancer Chemotherapy and Pharmacology.

Novel carbamate analogues of amsacrine with activity against non-cycling murine and human tumour cells

B. Baguley, G. Finlay, K. Holdaway, 2004, Cancer Chemotherapy and Pharmacology.

Emerging Role of Long Non-Coding RNA SOX2OT in SOX2 Regulation in Breast Cancer

M. Askarian-Amiri, C. Smart, B. Baguley, 2014, PloS one.

Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors.

A. J. Kaye, W. Denny, B. Baguley, 1997, Journal of medicinal chemistry.

Human Evolution: How Random Process Fulfils Divine Purpose

G. Finlay, 2008 .

POTENTIAL ANTITUMOR AGENTS. PART 43. SYNTHESIS AND BIOLOGICAL ACTIVITY OF DIBASIC 9-AMINOACRIDINE-4-CARBOXAMIDES, A NEW CLASS OF ANTITUMOR AGENT

W. Denny, B. Baguley, G. Atwell, 1985 .

Cytotoxicity of salicylaldehyde benzoylhydrazone analogs and their transition metal complexes: quantitative structure-activity relationships.

W. Denny, S. Gothe, G. Finlay, 1999, Journal of inorganic biochemistry.

Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.

J. A. Spicer, S. Gamage, W. Denny, 1999, Journal of medicinal chemistry.

Synthesis and cytotoxic activity of 7-oxo-7H-dibenz[f,ij]isoquinoline and 7-oxo-7H-benzo[e]perimidine derivatives.

W. Denny, B. Baguley, G. Finlay, 2001, Journal of medicinal chemistry.

Synthesis and antitumor activity of some indeno[1,2-b]quinoline-based bis carboxamides.

A. J. Kaye, W. Denny, B. Baguley, 2000, Bioorganic & medicinal chemistry.

Nitrogen, sulfur and oxygen donor adducts with copper(II) complexes of antitumor 2-formylpyridinethiosemicarbazone analogs: physicochemical and cytotoxic studies.

W. Denny, G. Finlay, J. Ranford, 1998, Journal of inorganic biochemistry.

Positioning of the carboxamide side chain in 11-oxo-11H-indeno[1,2-b]quinolinecarboxamide anticancer agents: effects on cytotoxicity.

A. J. Kaye, W. Denny, B. Baguley, 2001, Bioorganic & medicinal chemistry.

Synthesis and evaluation of unsymmetrical bis(arylcarboxamides) designed as topoisomerase-targeted anticancer drugs.

J. A. Spicer, S. Gamage, W. Denny, 2002, Bioorganic & medicinal chemistry.

Potential antitumor agents. 43. Synthesis and biological activity of dibasic 9-aminoacridine-4-carboxamides, a new class of antitumor agent.

W. Denny, B. Baguley, G. Atwell, 1984, Journal of medicinal chemistry.

A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells.

W. Wilson, B. Baguley, G. Finlay, 1984, Analytical biochemistry.

Dimeric analogues of non-cationic tricyclic aromatic carboxamides are a new class of cytotoxic agents.

J. A. Spicer, S. Gamage, W. Denny, 1999, Anti-cancer drug design.

Chemoprotection by 9-aminoacridine derivatives against the cytotoxicity of topoisomerase II-directed drugs.

W. Wilson, B. Baguley, G. Finlay, 1989, European journal of cancer & clinical oncology.

Selectivity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide towards Lewis lung carcinoma and human tumour cell lines in vitro.

B. Baguley, G. Finlay, 1989, European journal of cancer & clinical oncology.

The role of topoisomerases and RNA transcription in the action of the antitumour benzonaphthyridine derivative SN 28049

B. Baguley, G. Finlay, A. Porter, 2008, Cancer Chemotherapy and Pharmacology.

Differential actions of aclarubicin and doxorubicin: the role of topoisomerase I.

B. Baguley, G. Finlay, D. J. Bridewell, 1997, Oncology research.

Potential antitumor agents. 47. 3'-Methylamino analogues of amsacrine with in vivo solid tumor activity.

W. Denny, G. Rewcastle, B. Baguley, 1986, Journal of medicinal chemistry.

Comparison of in vitro activity of cytotoxic drugs towards human carcinoma and leukaemia cell lines.

W. Wilson, B. Baguley, G. Finlay, 1986, European journal of cancer & clinical oncology.

In vitro assessment ofN-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance

K. Paull, B. Baguley, G. Finlay, 2004, Cancer Chemotherapy and Pharmacology.

Proliferative assays for the assessment of radiosensitivity of tumor cell lines using 96-well microcultures

W. Wilson, B. Baguley, G. Finlay, 1993 .

The use of human cancer cell lines as a primary screening system for antineoplastic compounds.

B. Baguley, G. Finlay, 1984, European journal of cancer & clinical oncology.

Epigenetics in Melanoma

Euan J. Rodger, M. Askarian-Amiri, B. Baguley, 2018 .

Can ECIS Biosensor Technology Be Used to Measure the Cellular Responses of Glioblastoma Stem Cells?

E. S. Graham, G. Finlay, C. E. Angel, 2021, Biosensors.

Comprehensive analysis of inhibitory checkpoint ligand expression by glioblastoma cells

G. Finlay, C. E. Angel, W. Joseph, 2020, Immunology and cell biology.

Expression of inhibitory checkpoint ligands by Glioblastoma Multiforme cells and the implications of an enhanced stem cell-like phenotype

E. S. Graham, G. Finlay, C. E. Angel, 2019, bioRxiv.

ZFAS1: a long noncoding RNA associated with ribosomes in breast cancer cells

M. Askarian-Amiri, V. Figueiredo, D. Cameron-Smith, 2016, Biology Direct.

The Regulatory Role of Long Noncoding RNAs in Cancer Drug Resistance.

M. Askarian-Amiri, B. Baguley, G. Finlay, 2016, Methods in molecular biology.

Evidence That GRIN2A Mutations in Melanoma Correlate with Decreased Survival

M. During, M. Askarian-Amiri, R. Isaacs, 2014, Front. Oncol..

Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines

G. Rewcastle, M. Askarian-Amiri, B. Baguley, 2015, PloS one.

The Role of the Hippo Pathway in Melanocytes and Melanoma

B. Baguley, G. Finlay, J. Kim, 2013, Front. Oncol..

Selected GRIN2A mutations in melanoma cause oncogenic effects that can be modulated by extracellular glutamate.

B. Baguley, Taryn N. Green, M. Kalev-Zylinska, 2016, Cell calcium.

Derivation of Breast Cancer Cell Lines Under Physiological (5%) Oxygen Concentrations

S. Bohlander, M. Askarian-Amiri, B. Baguley, 2018, Front. Oncol..

Relationship between the structure of analogues of amsacrine and their degree of cross-resistance to adriamycin-resistant P388 leukaemia cells.

B. Baguley, G. Finlay, 1988, European journal of cancer & clinical oncology.

Epigenetic regulation in human melanoma: past and future

M. Askarian-Amiri, B. Baguley, G. Finlay, 2015, Epigenetics.

Cellular responses to methyl-N-[4-9-acridinylamino)-2-methoxyphenyl] carbamate hydrochloride, an analogue of amsacrine active against non-proliferating cells.

M. Dragunow, B. Baguley, G. Finlay, 1997, European journal of cancer.

Multiple Isoforms of ANRIL in Melanoma Cells: Structural Complexity Suggests Variations in Processing

M. Askarian-Amiri, Ali Oghabian, B. Baguley, 2017, International journal of molecular sciences.

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors

A. Shelling, B. Baguley, G. Finlay, 2013, Front. Genet..

Heterogeneity of expression of epithelial–mesenchymal transition markers in melanocytes and melanoma cell lines

B. Baguley, G. Finlay, E. Leung, 2013, Front. Genet..

Evidence for the Existence of Triple-Negative Variants in the MCF-7 Breast Cancer Cell Population

M. Askarian-Amiri, B. Baguley, G. Finlay, 2014, BioMed research international.

Short-term cultures of clinical tumor material: potential contributions to oncology research.

B. Baguley, G. Finlay, E. Marshall, 1999, Oncology research.

Genetics, molecular biology and colorectal cancer.

G. Finlay, Graeme J. Finlay, 1993, Mutation research.

Melphalan penetration of the blood-brain barrier via the neutral amino acid transporter in tumor-bearing brain.

W. Wilson, W. Pardridge, G. Finlay, 1992, Cancer research.

DNA-Binding Anticancer Drugs: One Target, Two Actions

B. Baguley, G. Finlay, Y. Chen, 2021, Molecules.

Modulation of Protein-DNA Interactions by Intercalating and Nonintercalating Agents

B. Baguley, G. Finlay, K. Holdaway, 1990 .

Interferon‐induced antibody suppression: a selective effect on high density, late responding precursor cells

R. Booth, G. Finlay, J. Marbrook, 1977, European journal of immunology.

Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent

B. Baguley, M. McKeage, G. Finlay, 2014, Cancer Chemotherapy and Pharmacology.

In vivo and in vitro assessment of the action of SN 28049, a benzonaphthyridine derivative targeting topoisomerase II, on the murine Colon 38 carcinoma

B. Baguley, G. Finlay, E. Richardson, 2011, Investigational New Drugs.

From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives.

J. Riou, B. Baguley, G. Finlay, 1996, European journal of cancer.

Potentiation by phenylbisbenzimidazoles of cytotoxicity of anticancer drugs directed against topoisomerase II.

B. Baguley, G. Finlay, 1990, European journal of cancer.

A carbamate analogue of amsacrine with activity against non-cycling cells stimulates topoisomerase II cleavage at DNA sites distinct from those of amsacrine.

Y. Pommier, J. Riou, B. Baguley, 1997, European journal of cancer.

Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines

A. Shelling, W. Phillips, P. Shepherd, 2012, BMC Cancer.

Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues.

K. Snow, B. Baguley, G. Finlay, 1990, Journal of the National Cancer Institute.

Derivatives of amsacrine: determinants required for high activity against Lewis lung carcinoma.

B. Baguley, G. Finlay, 1988, Journal of the National Cancer Institute.

Bis(phenazine-1-carboxamides): structure-activity relationships for a new class of dual topoisomerase I/II-directed anticancer drugs.

J. A. Spicer, S. Gamage, W. Denny, 2000, Journal of medicinal chemistry.

Real-Time Measurement of Melanoma Cell-Mediated Human Brain Endothelial Barrier Disruption Using Electric Cell-Substrate Impedance Sensing Technology

E. S. Graham, S. O'Carroll, G. Finlay, 2019, Biosensors.

Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).

B. Baguley, G. Finlay, D. J. Bridewell, 2001, Anti-cancer drug design.

Relationships between Signaling Pathway Usage and Sensitivity to a Pathway Inhibitor: Examination of Trametinib Responses in Cultured Breast Cancer Lines

G. Rewcastle, M. Askarian-Amiri, B. Baguley, 2014, PloS one.

Melanoma Cells Produce Large Vesicular-Bodies That Cause Rapid Disruption of Brain Endothelial Barrier-Integrity and Disassembly of Junctional Proteins

E. S. Graham, G. Finlay, C. E. Angel, 2023, International journal of molecular sciences.

Radiosensitivity of new and established human melanoma cell lines: comparison of [3H]thymidine incorporation and soft agar clonogenic assays.

B. Baguley, G. Finlay, E. Marshall, 1994, European journal of cancer.

Microculture-based chemosensitivity testing: a feasibility study comparing freshly explanted human melanoma cells with human melanoma cell lines.

B. Baguley, G. Finlay, E. Marshall, 1992, Journal of the National Cancer Institute.

Synthesis and cytotoxic activity of N-(2-diethylamino)ethylcarboxamide and other derivatives of 10H-quindoline.

A. J. Kaye, W. Denny, B. Baguley, 2002, Bioorganic & medicinal chemistry.

Synthesis of substituted indeno[1,2-b]quinoline-6-carboxamides, [1]benzothieno[3,2-b]quinoline-4-carboxamides and 10H-quindoline-4-carboxamides: evaluation of structure-activity relationships for cytotoxicity.

A. J. Kaye, W. Denny, B. Baguley, 2000, Bioorganic & medicinal chemistry.

Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.

J. A. Spicer, S. Gamage, W. Denny, 1997, Journal of medicinal chemistry.

Human tumor cells in culture stimulate glycosaminoglycan synthesis by human skin fibroblasts.

G. Finlay, M. Merrilees, 1985, Laboratory investigation; a journal of technical methods and pathology.

A comparison of the effects of aphidicolin and other inhibitors on topoisomerase II-directed cytotoxic drugs.

B. Baguley, G. Finlay, A. Haldane, 1993, Oncology research.

Abnormal insulin-receptor down regulation and dissociation of down regulation from insulin biological action in cultured human tumor cells.

G. Finlay, K. Mountjoy, I. Holdaway, 1987, Cancer research.

Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.

B. Baguley, G. Atwell, G. Finlay, 1999, Oncology research.

Synthesis and cytotoxic activity of carboxamide derivatives of benzimidazo[2,1-a]isoquinoline and pyrido[3',2':4,5]imidazo[2,1-a]isoquinoline.

W. Denny, B. Baguley, G. Finlay, 2000, Anti-Cancer Drug Design.

Indirect regulation of CYP2C19 gene expression via DNA methylation

N. Helsby, G. Finlay, K. Burns, 2018, Xenobiotica; the fate of foreign compounds in biological systems.

Stem Cell Niche Versus Cancer Stem Cell Niche – Differences and Similarities

B. Baguley, G. Finlay, 2009 .

Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta.

D. Sullivan, R. Lock, B. Baguley, 1999, Cancer Chemotherapy and Pharmacology.

Antibody responses of human lymphocytes in vitro. Enhancing effects of hydrocortisone.

R. Booth, G. Finlay, J. Marbrook, 1979, The Australian journal of experimental biology and medical science.